These companies have some important presentations scheduled for the last big oncology conference of the year.
News & Analysis: Bristol-Myers Squibb
These stocks are great picks to own regardless of which turns the market takes.
There are two reasons this Fool isn't selling his newfound shares from the Celgene buyout.
These two dividend-paying pharma stocks are basically immune to the whims of the broader economy.
HP rejected a buyout offer from Xerox, and the merger of Bristol-Myers Squibb and Celgene will complete this week.
Good news for Celgene is good news for Bristol-Myers Squibb -- and investors who like the big drugmaker's juicy dividend.
Is Bristol's stock still an attractive buy after last month's uptick?
While the results are promising, are they enough to threaten Merck's cancer superdrug Keytruda?
Opdivo didn't turn in an impressive performance, but BMS' other drugs generated more than enough growth to top Wall Street's estimates.
BMY earnings call for the period ending September 30, 2019.